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Assessing the validity, responsiveness and
reliability of the Recap measure of eczema
control
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DEAR EDITOR, Research comparing the effectiveness of different
eczema treatments is limited by inconsistency in both out-
comes assessed and the measures used. Harmonising Outcome
Measures for Eczema recommends a core set of outcomes to
be reported in all trials of eczema treatments.1 Recap of atopic
eczema (Recap) is a seven-item patient-reported instrument
recommended for capturing eczema control.2 Initial validation
work is encouraging, but the validity of Recap in different
populations is uncertain, as is its reliability and responsive-
ness.2,3
We investigated the acceptability, construct validity, respon-
siveness and reliability of Recap. This study was approved by
University of Bristol Research and Enterprise Development and
the Faculty of Health Sciences Research Ethics Committee (ref-
erence 2018-4887).
Online questionnaires were administered 2 weeks apart and
included Recap, validated scales of eczema severity [Patient-
Oriented Eczema Measure (POEM)] and quality of life
[Patient-Reported Outcomes Measurement Information System
(PROMIS)].4,5 People with eczema and carers of children with
eczema were recruited through social media and via patient
charities and organizations.6
To evaluate the construct validity of Recap, the following
hypotheses were prespecified:
(i) Eczema control worsens with increasing disease severity.
(ii)Poorer eczema control is associated with worse quality of
life.
(iii) Eczema control worsens with disease ‘bother’, as captured
by ‘How much bother has your eczema been over the past
week?’ (0 none, 10 maximum).
(iv) A self-reported improvement/worsening in eczema would
equate to a decrease/increase in Recap score, respectively.
The group of participants comprised 218 (574%) adults
and 162 (426%) children; for 156 (963%) children, ques-
tionnaires were completed by parent proxy. The mean age
was 342 years (SD 116, range 18–70) for adults, and
61 years (SD 47, range 0–17) for children. There were more
female adult participants (876%) than female children
(463%). Most respondents resided in the UK (n = 315,
875%) and were white (n = 311, 818%). The age and sex
characteristics of people at baseline (n = 380) and those who
completed (n = 188) or did not complete (n = 166) the
follow-up questionnaire were similar.
Recap had a high (997%) completion rate with a good dis-
tribution of scores [mean score adults 140 (SD 66); mean
score children 133 (SD 74)] and no floor or ceiling effects
were observed. Overall, 09% of adults and 37% of child par-
ticipants had the minimum Recap score; 28% of adults and
12% of child participants had the maximum Recap score. A
high internal consistency for Recap was observed (adult Cron-
bach’s a = 089, child Cronbach’s a = 092).
Hypothesized associations between Recap and other vari-
ables were observed. More severe disease (POEM) was associ-
ated with poorer eczema control (Recap) (Pearson’s
correlation coefficient, adults 082, P < 0001; children 090,
P < 0001). Poorer eczema control (Recap) was associated
with a worse self-rated global eczema control (Spearman’s
rank correlation coefficient, adults 073, P < 0001; children
085, P < 0001). Poorer eczema control (Recap) was also
associated with a poorer quality of life (PROMIS) (Pearson’s
coefficient, adult mental health 043, P < 0001; adult phys-
ical health 012, P = 00088; children overall health 029,
P = 00002). Recap was also associated with the bother score
(Pearson’s coefficient, adults 082, P < 0001; children 087,
P < 0001).
Recap had a high intraclass correlation coefficient (ICC) for
participants whose eczema severity was unchanged after
2 weeks [adult ICC = 085, n = 44, confidence interval (CI)
(07451–09166); child ICC = 089, n = 33 (CI 07992–
09488)], indicating good test–retest reliability. Responsive-
ness to change was demonstrated by the expected associations
between Recap and self-reported change in severity of eczema
(Table 1), and change scores for Recap and POEM. Partici-
pants who reported that their eczema was the ‘same’ at week
2 compared with baseline showed minimal change in Recap
scores [mean Recap change score, adults 02 (SD 05), chil-
dren 11 (SD 05)]. Moreover, self-reported changes in
eczema severity were associated with corresponding changes
in Recap score in the expected direction. Similarly, change
scores for Recap and POEM were positively associated for both
adults (Pearson’s correlation coefficient 066, P < 0001) and
children (Pearson’s correlation coefficient 072, P < 0001).
The main limitations of this study were the reliance on an
online survey and a low follow-up rate (563%). Recall bias,
and hence the ICC, were affected by different test–retest inter-
vals. We relied on participant self-report of eczema diagnosis
and symptoms; however, most participants (945% adults,
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932% children) met the UK working party criteria for atopic
eczema.6 Further studies should evaluate how Recap performs
in people with milder disease (most participants had moder-
ate-to-severe disease) and in different cultures and languages
(only an English language version was available).
In summary, Recap appears to have good acceptability,
validity, test–retest reliability and responsiveness to change.
Further work is required to investigate its validity in commu-
nity and clinic populations.
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Table 1 Change in Recap of atopic eczema (Recap) scores by self-reported change in eczema severity
Adult (n = 108) Child (n = 76)
Number (%) of participants Mean (SD) Recap change Number (%) of participants Mean (SD) Recap change
Much better 7 (65) 49 (09) 5 (66) 90 (41)
Better 30 (278) 41 (07) 16 (211) 51 (11)
Same 44 (407) 02 (05) 33 (434) 11 (05)
Worse 23 (213) 28 (06) 19 (250) 17 (10)
Much worse 4 (37) 40 (15) 3 (39) 33 (20)
Data were missing for four participants.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
2 Research letter
